Spondyloarthritis (SpA) refers to a group of HLA-B27-positive associated rheumatic diseases that share clinical and genetic features. The diseases and conditions that constitute the SpA group are defined by signs, symptoms, and radiographic findings, and consist of ankylosing spondylitis (AS), reactive arthritis (ReA), the SpA subsets psoriatic arthritis (PsA), Crohn’s disease (CD) and ulcerative colitis, and a subgroup of undifferentiated forms.

Traditionally, patients with SpA may be classified according to Amor, et al. and the European Spondyloarthropathy Study Group (ESSG) criteria. Patients fulfilling such criteria may then be classified or diagnosed according to specific criteria, clinical picture, or diagnostic tests for AS, ReA and SpA subsets PsA, CD and ulcerative colitis, for example. In general, patients with SpA that do not fulfill such classification or diagnostic-specific criteria remain unclassified and comprise the subgroup known as undifferentiated SpA (USpA).

USpA accounts for a significant but variable proportion of patients with SpA in the open population, in a group of relatives of probands with AS, and in hospital-based registries of SpA. As a group, USpA are mostly characterized by isolated episodes of peripheral arthritis and enthesitis, axial symptoms, and by a lower incidence of HLA-B27 versus AS.

As a group, SpA are characterized by overlapping of clinical manifestations over the disease course. For example, patients with AS may develop psoriasis and CD, patients with ReA may develop psoriasis, and patients with psoriasis may develop CD and AS. Similarly, patients with USpA may develop any specific clinical manifestation and fulfill specific diagnostic criteria some time later. In this context, it is clear that patients with SpA fulfilling specific criteria of more than 2 SpA constitute a “true SpA overlap,” while patients presenting with nonspecific or isolated manifestations of SpA without fulfilling specific SpA diagnostic or classification criteria constitute the group of USpA.

The series of events over the course of SpA, from undifferentiated to definite to overlapping, can take a variable amount of time and, as expected, no definition of this variable can be considered as a parameter to be fulfilled in classification or diagnostic criteria. Time definition may be of relevance in diagnosing or classifying patients with USpA and patients classified as axial and peripheral SpA according to the Assessment in Spondyloarthritis International Society (ASAS) new criteria. Two related questions in this regard are simple but difficult to answer: How long should USpA be considered the earliest form of definite SpA (e.g., AS), or be considered a particular form of SpA that never evolves into definite SpA? Although we don’t know the answer, there is information from studies assessing long-term outcome in USpA and looking for prognostic factors.

In this issue of The Journal, Sampaio-Barros, et al. present data on 5 to 10-year followup in patients with USpA fulfilling ESSG criteria who have no radiographic sacroiliitis, psoriasis, CD, ulcerative colitis, or triggering infection. By 10-year followup, a relatively low 35% of 42 patients with USpA had progressed to AS. In their article and in most longer studies of USpA, we may recognize 2 of the 4 types of USpA proposed by Zeidler, et al.: (1) a subgroup of patients representing the early stage of a definite, well categorized SpA (e.g., AS); and (2) a second subgroup consisting of patients with definite USpA. According to Sampaio-Barros, et al. and other findings, an additional subclass of patients in the latter subgroup would include those going into remission.

Origin of USpA. The recognition of clinical forms that later became USpA dates back to Khan, et al. in 1983, and Burns and Calin in 1984, in which they described this subgroup of patients. This type of patient has since been recognized, classified, and diagnosed according to the most common features, particularly peripheral arthritis, enthesitis, and extraarticular symptoms. Patients were also
followed up over years to determine the proportion fulfilling AS criteria\textsuperscript{21} and to identify factors involved in the process. Retrospective studies on outcome in USpA. Short and longterm followup studies referred to AS as the most important outcome in USpA. In 2 shorter followup studies, the proportion of patients fulfilling AS criteria 24 and 28 months after onset were 10\%\textsuperscript{22} and 36\%\textsuperscript{23}, respectively. In the Schattenkirchner and Krüger study\textsuperscript{24}, the percentage reached 25\% within 2 to 6 years, versus Huerta-Sil’s finding of 42\% by 3 years after symptom onset\textsuperscript{25}. Two further studies\textsuperscript{16,26} found AS in 25\% and 36\% by 5 years after onset. Few followup studies reached 10 years or more. Interestingly, however, the proportion of patients with AS as reported by Mau, et al\textsuperscript{10} and Kumar, et al\textsuperscript{17} was 66\% and 68\% at 10- and 11-year followup; this is in contrast with Sampaio-Barros’s\textsuperscript{14} present report, in which only 35.7\% of the patients were diagnosed as having AS 10 years after onset.

The outcome of patients not fulfilling AS criteria has been scarcely reported. In Kumar’s study\textsuperscript{17} 2 (9\%) patients entered into remission and one (4.5\%) developed PsA. In Mau’s longterm followup\textsuperscript{16} one (1.1\%) patient had self-limited disease and 2 (2.2\%) PsA. Sampaio-Barros, et al\textsuperscript{14} report that 40.5\% entered into remission, 16.7\% remained undifferentiated, and 7.1\% developed PsA.

In children, the proportion of patients with USpA and USpA-like clinical forms fulfilling AS criteria throughout the followup period ranges from 66\% to 90\% within 10 years of disease\textsuperscript{27-30}.

Some descriptions do not refer to AS as an outcome measure. In Sambrook’s followup\textsuperscript{31} of patients with HLA-B27 associated peripheral arthritis, 10\% of patients fulfilled ReA triad criteria and 55\% entered into remission. However, there was only one case with SpA and no case with AS diagnosed during followup. On the other hand, a number of papers have referred to “late-onset SpA” as SpA starting after age 50 years\textsuperscript{32-35}. Clinical manifestations in this group are also diverse, but mainly consist of peripheral joint involvement. Remarkably, presence of systemic and extrarticular manifestations indicates the need for careful assessment to rule out a number of diverse conditions. To date, there is still no information on the percentage of patients with late-onset SpA evolving into AS or definite SpA.

Differences across studies mentioned above seem to be related to disease definition at the time of inclusion. Diagnosis varied from “HLA-B27-negative associated oligoarthritis”\textsuperscript{24} to “possible ankylosing spondylitis”\textsuperscript{16}, “possible SpA”\textsuperscript{26}, and “undifferentiated SpA”\textsuperscript{17,22,25}. Disease duration in various studies extended more than 10 years (i.e., the sum of the duration of the disease at baseline and the duration of followup); therefore, diagnosis of USpA does not necessarily mean early or recent SpA. Further explanations of differences between studies include the assessment and outcome measures and ethnicity.

Most patients with USpA present with any of 3 types of symptoms: peripheral arthritis, inflammatory back pain (IBP), and a combination of peripheral arthritis and IBP. Definitely, the type of SpA symptoms at presentation depends on the definition of disease at time of study inclusion.

Manifestations at onset. The presentation of SpA in Mau, et al\textsuperscript{16} was mostly axial, whereas in Kumar, et al\textsuperscript{30}, disease most frequently affected peripheral sites. Although inclusion criteria for most studies were mainly oriented to peripheral arthritis, Mau, et al\textsuperscript{16} included patients with possible AS. In contrast, studies from Sampaio-Barros, et al\textsuperscript{22}, Huerta-Sil, et al\textsuperscript{25}, and Kumar, et al\textsuperscript{17} relied on ESSG criteria\textsuperscript{3}. Enthesitis, dactylitis, anterior uveitis, inflammatory bowel disease, cardiac rhythm disturbances, or other symptoms may occur as the earliest manifestation of USpA.

Some studies have been performed in Europe\textsuperscript{16,23-24,26}, and some in Latin America\textsuperscript{14,22,25} and Asia\textsuperscript{17}. Although no formal comparisons between ethnic groups have been made, retrospective reviews of patients with AS have shown that Caucasians from Europe and North America present with IBP more often than patients from Latin America, Asia, the Middle East, and Africa, where peripheral symptoms are much more common\textsuperscript{36,37}. Differences between ethnic groups might reflect not only the influence of genetic factors, but also a role for geographical or environmental factors.

USpA as an early form of AS. The identification of patients with USpA could enable physicians to recognize patients with AS at an earlier stage and treat them accordingly. Overall, diagnosis of AS\textsuperscript{21}, which requires a certain level of sacroiliac joint damage to be visible on radiographs, is usually, but not always, made around 8 years after onset\textsuperscript{38}. Response to tumor necrosis factor-α (TNF-α) blockers, as measured by the proportion of patients reaching 50\% or greater reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), surpasses 70\% in patients with disease duration < 10 years, but is scarcely 30\% in patients with duration > 20 years\textsuperscript{39,40}.

Fulfillment of AS criteria\textsuperscript{21} by patients with USpA in the course of disease has been inconsistently associated with baseline characteristics, specifically uveitis\textsuperscript{16,25,26}, HLA-B27\textsuperscript{16,22}, alternate gluteal pain\textsuperscript{22}, peripheral arthritis\textsuperscript{23}, high erythrocyte sedimentation rate\textsuperscript{16}, or C-reactive protein (CRP)\textsuperscript{25}, recurrent oligoarthritis\textsuperscript{24}, and low-grade radiographic sacroiliitis\textsuperscript{25}. However, only the reports by Huerta-Sil, et al\textsuperscript{25} and Sampaio-Barros, et al\textsuperscript{14} have identified risk factors for AS in patients with USpA. Huerta-Sil, et al\textsuperscript{25} found radiographic sacroiliitis grade < 2 bilateral, or grade < 3 unilateral (OR 11.18, 95\% CI 2.59, 48.16; p = 0.001), particularly grade 1 bilateral (OR 12.58, 95\% CI 1.33, 119.09; p = 0.027), and previous uveitis (OR 19.25, 95\% CI 1.72, 214.39; p = 0.001) to be prognostic of AS; and Sampaio-Barros, et al\textsuperscript{14} found risk factors HLA-B27 (OR 6.720, 95\% CI 11.45, 39.43; p = 0.035) and buttok pain (OR...
is important information derived from the study of patients with SpA and particularly USpA with short disease duration. Although the purpose, inclusion criteria, and variables analyzed differ across different studies, each provides data on percentages of patients fulfilling AS and other definite SpA criteria shortly after onset, and the characteristics of early disease.

The Maastricht early SpA clinic (ESPAC) study of 68 patients with IBP with < 2 years of symptoms referred from various clinical departments showed that 14 patients developed AS within 2 years of symptoms and 36 developed SpA according to Amor, ESSG, and Berlin criteria. PsA accounted for 24% and IBD and uveitis for 15% each. Based on real-world findings, that report proposes modifications to improve the diagnostic properties of the Berlin algorithm, specifically the step in which MRI and HLA-B27 investigations should be ordered in patients with IBP.

In the Leeds IBP clinic found that in patients with IBP with < 2 years of symptoms had AS (HLA-B27 in 85%) after around 8 years of followup; 2 cases each were associated with IBD or reactive arthritis, and one with psoriasis. Of the 27 patients without AS, 3 had psoriatic SpA, 6 had reactive SpA, 1 had IBD SpA, and 17 had undifferentiated SpA. MR sacroiliitis (n = 10 at baseline, all HLA-B27-positive) had 92% specificity for AS. Combined moderate and severe MR sacroiliitis, regardless of HLA-B27 status, yielded 62% specificity and 77% sensitivity for AS. The likelihood ratio of combined severe MR sacroiliitis and HLA-B27 was 8.0 for AS.

The German Spondyloarthritis Inception Cohort (GESPIC) included 226 patients (mean age 36.1 ± 10.6 yrs; 42.9% male) with axial SpA (nonradiographic SpA or radiographic sacroiliitis grades 0 or 1) whose disease duration was 2.6 ± 1.7 years. The manifestations that most frequently occurred in this group were IBP (100%), peripheral arthritis (40.9%), peripheral enthesitis (43.6%), uveitis (12.4%), psoriasis (9.8%), dactylitis (4.0%), and IBD (1.8%). Male sex was a risk factor for developing radio-graphic sacroiliitis (OR 2.38, 95% CI 1.9, 4.7; p = 0.014) and > 1 syndesmophyte (OR 2.40, 95% CI 1.05, 5.5; p = 0.039); CRP ≤ 6 mg/l was a risk factor for developing the latter (OR 2.59, 95% CI 1.23, 5.45; p = 0.012) and for > 1 bridging syndesmophyte (OR 2.89, 95% CI 1.05, 7.79; p = 0.036).
ed of low back pain [n = 24 (56%)], sacroiliac syndrome [n = 15 (35%)], or neck pain [n = 2 (5%)]. Peripheral arthritis affecting the upper limbs or lower limbs occurred in 7 (16%) and 15 (35%) patients, and dactylitis in 3 (7%) or enthesitis in 12 (28%). A comparison between that group and patients with > 10 years of disease (n = 122) revealed a nonsignificant decrease of the prevalence of each variable, excepting enthesitis, which changed from 28% to 15% (p = 0.05).

The Iberoamerican Registry of Spondyloarthritis (Registro de Espondiloartritis de Iberoamérica or RESPONDIA)\(^{(47)}\) has gathered information from 10 countries. RESPONDIA includes 180 patients with USpA whose mean age and duration of disease were 38.1 ± 12.9 years and 11.9 ± 15.4 years, respectively. Yet around 25% of these patients had disease duration < 2 years. Preliminary data suggest that most patients with USpA present to clinic with peripheral rather than axial symptoms and that a significant percentage of them have axial and peripheral involvement throughout the disease course.

It is noteworthy that a significant proportion of patients in the above studies were diagnosed with AS in less than 2\(^{(42,45)}\) or 5\(^{(44)}\) years of disease. These findings suggest that diagnosis of AS in some patients made early in the disease course is at a time when the effect of TNF-α blockers may be significant.

GESPIC\(^{(44)}\), REGISPONSER\(^{(45)}\), and RESPONDIA\(^{(46)}\) compared clinical features of USpA with those found in patients with AS. While disease duration of AS and USpA in the GESPIC group was significantly different, the REGISPONSER comparison included patients with AS and USpA with < 2 years of symptoms. Overall, the comparison between USpA and AS in the 3 studies\(^{(44-46)}\) showed a lower prevalence of women and HLA-B27-positive patients in the group of USpA, and more severe disease in patients with AS in regard to radiographic findings and patient self-reported outcome measures. There were differences between groups regarding the prevalence of some clinical symptoms, but the disease pattern was rather similar. At first glance, short-term USpA resembles early stage AS.

**Adapting to new names and classification criteria.** We are going through a transition: from SpA to axial and peripheral SpA, from ESSG and Amor criteria to ASAS axial and peripheral criteria, and from retrospective studies to prospective cohorts and early SpA or IBP clinics. A series of strategies is leading to a common end: to identify patients with SpA in the early inflammatory stage and those at risk of developing structural change or damage, in order to provide them with effective therapy as early as possible. While the longterm efficacy of new therapies, specifically disease-modifying TNF blockers, is still to be determined, their role in disease remission warrants their use for symptom control and improvement of health related quality of life.

**RUBEN BURGOS-VARGAS, MD,**
Senior Investigator and Professor of Medicine, Department of Rheumatology, Hospital General de México, Faculty of Medicine, Universidad Nacional Autónoma de México;

**JULIO C. CASASOLA-VARGAS, MD,**
Staff Rheumatologist, Department of Rheumatology, Hospital General de México, Dr. Balmis 148, colonia Doctores, México DF 06720

Address correspondence to Prof. Burgos-Vargas; E-mail: burgosv@prodigy.net.mx

**REFERENCES**


J Rheumatol 2010;37:1091–5; doi:10.3899/jrheum.100413